Table 3.
Association of clinical and pathologic parameters with Gleason Score (GS) group: upgrading from biopsy GS ≤7(3 + 4) to GS ≥7(4 + 3) at radical prostatectomy.
| variables | Upgrade (n = 28) | No-upgrade (n = 89) | t value (95%CI) | p-value |
|---|---|---|---|---|
| Age, year | ||||
| Median (IQR) | 70.0 (65.0–72.0) | 67.0 (63.0–71.0) | 1.49 (−0.61, 4.14) | 0.130 |
| Mean (SD) | 68.8 (5.5) | 67.0 (5.3) | ||
| PSA, ng/ml | ||||
| Median (IQR) | 11.5 (7.3–16.2) | 8.8 (6.9–10.5) | 3.34 (1.98, 7.78) | 0.001 |
| Mean (SD) | 14.5 (10.1) | 9.6 (5.4) | ||
| No. of positive cores | ||||
| Median (IQR) | 3.0 (1.0–5.0) | 3.0 (2.0–5.0) | 0.47 (−1.07, 1.72) | 0.641 |
| Mean (SD) | 4.0 (3.3) | 3.6 (2.8) | ||
| Maximum % cancer/core | ||||
| Median (IQR) | 45.0(20.0–76.3) | 30.0 (20.0–50.0) | 1.82 (−0.98, 23.02) | 0.071 |
| Mean (SD) | 48.2(32.0) | 37.2 (26.6) | ||
| Pathology weight (continuous), gram | ||||
| Median (IQR) | 62.0 (51.0–76.5) | 63.0 (47.6–86.8) | 1.24 (−5.43, 23.73) | 0.216 |
| Mean (SD) | 64.7 (18.3) | 73.9 (36.8) | ||
| PSAD (continuous), ng/ml2 | ||||
| Median (IQR) | 0.2 (0.1–0.2) | 0.1 (0.1–0.2) | 3.21 (0.04, 0.16) | 0.002 |
| Mean (SD) | 0.3 (0.2) | 0.2 (0.10) | ||
| Clinical stage (%) | ||||
| ≤T2a | 16 | 69 | 1.83 (−0.02, 0.51) | 0.070 |
| T2b/c | 9 | 14 | ||
| T3 | 3 | 6 | ||
| USWE (continuous), kPa | ||||
| Median (IQR) | 145.1 (128.8–168.5) | 128.7 (115.3–147.6) | 2.64 (4.98, 34.84) | 0.009 |
| Mean (SD) | 154.2 (42.3) | 134.3 (31.4) | ||
| PI-RADS | ||||
| ≤3 | 1 | 19 | 2.23 (0.02, 0.34) | 0.028 |
| 4 and 5 | 27 | 69 | ||
| Not reported | 0 | 1 | ||